BioXcel Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $120 | $168 | $366 | $214 |
Gross Profit | -62 | 168 | -466 | -956 |
EBITDA | -15,852 | -6,855 | -6,750 | -9,783 |
EBIT | -15,927 | -7,254 | -6,827 | -9,860 |
Net Income | -19,187 | -7,254 | -10,859 | -13,650 |
Net Change In Cash | 120 | 168 | 366 | 214 |
Free Cash Flow | -12,575 | -12,043 | -14,809 | -16,338 |
Cash | 17,435 | 31,013 | 29,854 | 40,387 |
Basic Shares | 7,843 | 2,535 | 2,535 | 16,701 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $2,266 | $1,380 | $375 | $0 |
Gross Profit | 123 | 120 | 355 | -297 |
EBITDA | -44,161 | -165,421 | -157,384 | -106,638 |
EBIT | -44,470 | -165,739 | -157,711 | -106,935 |
Net Income | -59,599 | -179,053 | -165,757 | -106,630 |
Net Change In Cash | 2,266 | 1,380 | 375 | 0 |
Cost of Revenue | -39,243 | 19,849 | ||
Free Cash Flow | -72,027 | -155,026 | -135,480 | -82,598 |
Cash | 29,854 | 65,221 | 193,725 | 232,968 |
Basic Shares | 2,535 | 29,129 | 28,015 | 26,373 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$2.45 |
2025-03-31 | -$1.50 |
2024-12-31 | -$3.56 |
2024-09-30 | -$0.32 |
